A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

Administered By

Awarded By

Contributors

Start/End

  • June 18, 2020 - February 10, 2022